Literature DB >> 22553961

Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure.

Jian Li, Wei Zhang, Wen-Ying Kang, Xin-Xin Cao, Ming-Hui Duan, Dao-Bin Zhou.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22553961     DOI: 10.3109/10428194.2012.690515

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  5 in total

1.  Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation.

Authors:  Yoshimi Ishii; Etsuko Yamazaki; Yasufumi Ishiyama; Eri Yamamoto; Yukako Hattori; Maki Hagihara; Naoto Tomita; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2013-10-29       Impact factor: 2.490

Review 2.  POEMS Syndrome: an Enigma.

Authors:  Rahma Warsame; Uday Yanamandra; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 4.213

3.  Portal hypertension as the initial manifestation of POEMS syndrome: a case report.

Authors:  Lina Wu; Yue Li; Fang Yao; Chongmei Lu; Jian Li; Weixun Zhou; Jiaming Qian
Journal:  BMC Hematol       Date:  2017-05-11

4.  Treatment and outcomes of POEMS syndrome: changes in the past 20 years.

Authors:  Yan-Ying Yu; Xue-Min Gao; Hao Zhao; Hao Cai; Jun Feng; Lu Zhang; Xin-Xin Cao; Daobin Zhou; Jian Li
Journal:  Blood Cancer J       Date:  2021-08-14       Impact factor: 11.037

5.  Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.

Authors:  Tomoki Suichi; Sonoko Misawa; Yukari Sekiguchi; Kazumoto Shibuya; Keigo Nakamura; Hiroki Kano; Yuya Aotsuka; Ryo Otani; Marie Morooka; Shokichi Tsukamoto; Yusuke Takeda; Naoya Mimura; Chikako Ohwada; Emiko Sakaida; Satoshi Kuwabara
Journal:  Intern Med       Date:  2022-09-01       Impact factor: 1.282

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.